Spots Global Cancer Trial Database for 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
Official Title: A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Resminostat (4SC-201) in Combination With a Second-line Treatment in Patients With K-ras Mutated Advanced Colorectal Carcinoma
Study ID: NCT01277406
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of 4SC-201 (Resminostat) in combination with FOLFIRI and whether 4SC-201 (Resminostat) is effective and safe in combination FOLFIRI versus FOLFIRI alone in the treatment of advanced colorectal carcinoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
KTB-Klinik für Tumorbiologie, Klinik für Internistische Onkologie, Freiburg, , Germany
University of Heidelberg, Heidelberg, , Germany
Universitaetsklinikum Tuebingen; Med. Klinik und Poliklinik II, Tuebingen, , Germany
Contact Details
Name: Dirk Jäger, Prof. Dr.
Affiliation: Medical Oncology National Centre for Tumor Diseases (NCT); University of Heidelberg
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
